title: Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
abstract: Forearm bone mineral content (BMC) was measured sequentially on and off anabolic steroid therapy in 52 postmenopausal women with osteoporosis. The steroid used was nandrolone decanoate in a dose of 50 mg every two weeks by intramuscular injection. In 16 of the patients nandrolone was given first (for 6.2 +/- 0.6 months) followed by a control period (6.1 +/- 1.0 months) and in 36 there was an initial control period (9.5 +/- 1.1 months) followed by nandrolone (for 5.8 +/- 0.4 months). Any other therapy was continued unchanged during both treatment and control periods. There was a significant rise in BMC on nandrolone (p less than 0.001) and a nonsignificant fall in BMC off nandrolone. The difference between the rates of change on and off nandrolone was highly significant (+53 vs. -7 mg/cm/year; p less than 0.001).
authors: Division of Clinical Chemistry, Institute of Medical and Veterinary Science, Adelaide, South Australia.
authors: A G
authors: AG
authors: Need
authors: M
authors: M
authors: Horowitz
authors: H A
authors: HA
authors: Morris
authors: C J
authors: CJ
authors: Walker
authors: B E
authors: BE
authors: Nordin
mesh_terms: D000368:Aged; D045930:Anabolic Agents / Q000627:therapeutic use; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000032:analysis*; D002118:Calcium / Q000627:therapeutic use; D005260:Female; D005542:Forearm; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D008903:Minerals / Q000032:analysis*; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D010024:Osteoporosis / Q000517:prevention & control*
chemical_list: D045930:Anabolic Agents; D008903:Minerals; D009277:Nandrolone; D000077603:Nandrolone Decanoate; D002118:Calcium